The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical implications of anti-thyroglobulin antibody measurement before surgery in thyroid cancer

  • Jo, Kwanhoon (Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea) ;
  • Lim, Dong-Jun (Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea)
  • Received : 2018.08.04
  • Accepted : 2018.10.05
  • Published : 2018.11.01
⟨ Previous Next ⟩

Abstract

Thyroglobulin antibody (TgAb) is a class G immunoglobulin and a conventional marker for thyroid autoimmunity. From a clinical perspective, TgAb is less useful than thyroid peroxidase antibodies for predicting thyroid dysfunction. However, TgAb is found more frequently in differentiated thyroid cancer (DTC) and can interfere with thyroglobulin (Tg) measurements, which are used to monitor the recurrence or persistence of DTC. Recent studies suggested a small but consistent role for preoperative TgAb in predicting DTC in thyroid nodules, and in reflecting adverse tumor characteristics or prognosis, including lymph node metastasis, but this is still controversial. Postoperative TgAb can serve as a biomarker for remnant thyroid tissue, so follow-up measures of TgAb are useful for predicting cancer recurrence in DTC patients. Since high serum TgAb levels may also affect the fine needle aspiration washout Tg levels from suspicious lymph nodes of DTC patients, it is important to use caution when interpreting the washout Tg levels in patients who are positive for TgAb.

Keywords

References

  1. Hegedus L. Clinical practice: the thyroid nodule. N Engl J Med 2004;351:1764-1771. https://doi.org/10.1056/NEJMcp031436
  2. Hori M, Katanoda K. Morphological distribution of thyroid cancer from Cancer Incidence in Five Continents Vol. X. Jpn J Clin Oncol 2015;45:1182. https://doi.org/10.1093/jjco/hyv176
  3. Cho BY, Choi HS, Park YJ, et al. Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades. Thyroid 2013;23:797-804. https://doi.org/10.1089/thy.2012.0329
  4. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1-133. https://doi.org/10.1089/thy.2015.0020
  5. Bayer MF, Kriss JP. Immunoradiometric assay for serum thyroglobulin: semiquantitative measurement of thyroglobulin in antithyroglobulin-positive sera. J Clin Endocrinol Metab 1979;49:557-564. https://doi.org/10.1210/jcem-49-4-557
  6. Schneider AB, Pervos R. Radioimmunoassay of human thyroglobulin: effect of antithyroglobulin autoantibodies. J Clin Endocrinol Metab 1978;47:126-137. https://doi.org/10.1210/jcem-47-1-126
  7. Frohlich E, Wahl R. Thyroid autoimmunity: role of anti-thyroid antibodies in thyroid and extra-thyroidal diseases. Front Immunol 2017;8:521. https://doi.org/10.3389/fimmu.2017.00521
  8. Roitt IM, Doniach D, Campbell PN, Hudson RV. Auto-antibodies in Hashimoto's disease (lymphadenoid goitre). Lancet 1956;271:820-821.
  9. Rose NR, Witebsky E. Studies on organ specificity. V. Changes in the thyroid glands of rabbits following active immunization with rabbit thyroid extracts. J Immunol 1956;76:417-427.
  10. Barin JG, Talor MV, Sharma RB, Rose NR, Burek CL. Iodination of murine thyroglobulin enhances autoimmune reactivity in the NOD.H2 mouse. Clin Exp Immunol 2005;142:251-259. https://doi.org/10.1111/j.1365-2249.2005.02908.x
  11. Li Y, Teng D, Shan Z, et al. Antithyroperoxidase and antithyroglobulin antibodies in a five-year follow-up survey of populations with different iodine intakes. J Clin Endocrinol Metab 2008;93:1751-1757. https://doi.org/10.1210/jc.2007-2368
  12. Latrofa F, Ricci D, Grasso L, et al. Characterization of thyroglobulin epitopes in patients with autoimmune and non-autoimmune thyroid diseases using recombinant human monoclonal thyroglobulin autoantibodies. J Clin Endocrinol Metab 2008;93:591-596. https://doi.org/10.1210/jc.2007-1199
  13. Caturegli P, Kuppers RC, Mariotti S, et al. IgG subclass distribution of thyroglobulin antibodies in patients with thyroid disease. Clin Exp Immunol 1994;98:464-469.
  14. Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998;83:1121-1127.
  15. Feldt-Rasmussen U, Rasmussen AK. Autoimmunity in differentiated thyroid cancer: significance and related clinical problems. Hormones (Athens) 2010;9:109-117. https://doi.org/10.14310/horm.2002.1261
  16. Kebebew E, Treseler PA, Ituarte PH, Clark OH. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J Surg 2001;25:632-637. https://doi.org/10.1007/s002680020165
  17. Kim ES, Lim DJ, Baek KH, et al. Thyroglobulin antibody is associated with increased cancer risk in thyroid nodules. Thyroid 2010;20:885-891. https://doi.org/10.1089/thy.2009.0384
  18. Braverman LE, David DS, Werner SC, Ingbar SH. Werner & Ingbar's the Thyroid: A Fundamental and Clinical Text. Philadelphia (PA): Lippincott Williams & Wilkins, 2013.
  19. McLachlan SM, Rapoport B. Why measure thyroglobulin autoantibodies rather than thyroid peroxidase autoantibodies? Thyroid 2004;14:510-520. https://doi.org/10.1089/1050725041517057
  20. Vasileiadis I, Boutzios G, Charitoudis G, Koukoulioti E, Karatzas T. Thyroglobulin antibodies could be a potential predictive marker for papillary thyroid carcinoma. Ann Surg Oncol 2014;21:2725-2732. https://doi.org/10.1245/s10434-014-3593-x
  21. Grani G, Calvanese A, Carbotta G, et al. Thyroid autoimmunity and risk of malignancy in thyroid nodules submitted to fine-needle aspiration cytology. Head Neck 2015;37:260-264. https://doi.org/10.1002/hed.23587
  22. Hosseini S, Payne RJ, Zawawi F, et al. Can preoperative thyroglobulin antibody levels be used as a marker for well differentiated thyroid cancer? J Otolaryngol Head Neck Surg 2016;45:31. https://doi.org/10.1186/s40463-016-0143-5
  23. Qin J, Yu Z, Guan H, Shi L, et al. High thyroglobulin antibody levels increase the risk of differentiated thyroid carcinoma. Dis Markers 2015;2015:648670.
  24. Anil C, Goksel S, Gursoy A. Hashimoto's thyroiditis is not associated with increased risk of thyroid cancer in patients with thyroid nodules: a single-center prospective study. Thyroid 2010;20:601-606. https://doi.org/10.1089/thy.2009.0450
  25. Rago T, Di Coscio G, Ugolini C, et al. Clinical features of thyroid autoimmunity are associated with thyroiditis on histology and are not predictive of malignancy in 570 patients with indeterminate nodules on cytology who had a thyroidectomy. Clin Endocrinol (Oxf ) 2007;67:363-369. https://doi.org/10.1111/j.1365-2265.2007.02892.x
  26. Lun Y, Wu X, Xia Q, et al. Hashimoto's thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis. Otolaryngol Head Neck Surg 2013;148:396-402. https://doi.org/10.1177/0194599812472426
  27. Wu X, Lun Y, Jiang H, et al. Coexistence of thyroglobulin antibodies and thyroid peroxidase antibodies correlates with elevated thyroid-stimulating hormone level and advanced tumor stage of papillary thyroid cancer. Endocrine 2014;46:554-560. https://doi.org/10.1007/s12020-013-0121-x
  28. Castagna MG, Belardini V, Memmo S, et al. Nodules in autoimmune thyroiditis are associated with increased risk of thyroid cancer in surgical series but not in cytological series: evidence for selection bias. J Clin Endocrinol Metab 2014;99:3193-3198. https://doi.org/10.1210/jc.2014-1302
  29. Hadjisavva IS, Dina R, Talias MA, Economides PA. Prevalence of cancer in patients with thyroid nodules in the island of cyprus: predictive value of ultrasound features and thyroid autoimmune status. Eur Thyroid J 2015;4:123-128. https://doi.org/10.1159/000430438
  30. Selek A, Cetinarslan B, Tarkun I, Canturk Z, Ustuner B, Akyay Z. Thyroid autoimmunity: is really associated with papillary thyroid carcinoma? Eur Arch Otorhinolaryngol 2017;274:1677-1681. https://doi.org/10.1007/s00405-016-4414-6
  31. Kim EY, Kim WG, Kim WB, et al. Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma. Clin Endocrinol (Oxf ) 2009;71:581-586. https://doi.org/10.1111/j.1365-2265.2009.03537.x
  32. Durante C, Tognini S, Montesano T, et al. Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies. Thyroid 2014;24:1139-1145. https://doi.org/10.1089/thy.2013.0698
  33. McLeod DS, Cooper DS, Ladenson PW, et al. Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. Thyroid 2014;24:35-42. https://doi.org/10.1089/thy.2013.0062
  34. Jo K, Kim MH, Ha J, et al. Prognostic value of preoperative anti-thyroglobulin antibody in differentiated thyroid cancer. Clin Endocrinol (Oxf ) 2017;87:292-299. https://doi.org/10.1111/cen.13367
  35. Zhang T, Song LP, Zhao T, Gao W, Lin YS. Effect of lymph node metastasis on change of positive thyroglobulin antibody in differentiated thyroid carcinoma after initial treatment. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2017;39:539-543.
  36. Li W, Ming H, Sun D, et al. The relationship between BRAFV600E, NF-${\kappa}B$ and TgAb expression in papillary thyroid carcinoma. Pathol Res Pract 2017;213:183-188. https://doi.org/10.1016/j.prp.2016.12.022
  37. Nishikawa M, Otsuki T, Ota A, et al. Induction of tumorspecific immune response by gene transfer of Hsp70- cell-penetrating peptide fusion protein to tumors in mice. Mol Ther 2010;18:421-8. https://doi.org/10.1038/mt.2009.203
  38. Boon T, Gajewski TF, Coulie PG. From defined human tumor antigens to effective immunization? Immunol Today 1995;16:334-6. https://doi.org/10.1016/0167-5699(95)80149-9
  39. Siraj AK, Masoodi T, Bu R, et al. Genomic profiling of thyroid cancer reveals a role for thyroglobulin in metastasis. Am J Hum Genet 2016;98:1170-1180. https://doi.org/10.1016/j.ajhg.2016.04.014
  40. Gorges R, Maniecki M, Jentzen W, et al. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol 2005;153:49-55. https://doi.org/10.1530/eje.1.01940
  41. Chiovato L, Latrofa F, Braverman LE, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 2003;139(5 Pt 1):346-351. https://doi.org/10.7326/0003-4819-139-5_Part_1-200309020-00010
  42. Hsieh CJ, Wang PW. Sequential changes of serum antithyroglobulin antibody levels are a good predictor of disease activity in thyroglobulin-negative patients with papillary thyroid carcinoma. Thyroid 2014;24:488-493. https://doi.org/10.1089/thy.2012.0611
  43. Kim WG, Yoon JH, Kim WB, et al. Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2008;93:4683-4689. https://doi.org/10.1210/jc.2008-0962
  44. Lim DJ, O JH, Kim MH, et al. Clinical significance of observation without repeated radioiodine therapy in differentiated thyroid carcinoma patients with positive surveillance whole-body scans and negative thyroglobulin. Korean J Intern Med 2010;25:408-414. https://doi.org/10.3904/kjim.2010.25.4.408
  45. Dewi AR, Darmawan B, Kartamihadja AH, Hidayat B, Masjhur JS. Antithyroglobulin antibody as a marker of successful ablation therapy in differentiated thyroid cancer. World J Nucl Med 2017;16:15-20. https://doi.org/10.4103/1450-1147.174714
  46. Trimboli P, Zilioli V, Imperiali M, Giovanella L. Thyroglobulin autoantibodies before radioiodine ablation predict differentiated thyroid cancer outcome. Clin Chem Lab Med 2017;55:1995-2001.
  47. Snozek CL, Chambers EP, Reading CC, et al. Serum thyroglobulin, high-resolution ultrasound, and lymph node thyroglobulin in diagnosis of differentiated thyroid carcinoma nodal metastases. J Clin Endocrinol Metab 2007;92:4278-81. https://doi.org/10.1210/jc.2007-1075
  48. Shin HJ, Lee HS, Kim EK, Moon HJ, Lee JH, Kwak JY. A study on serum antithyroglobulin antibodies interference in thyroglobulin measurement in fine-needle aspiration for diagnosing lymph node metastasis in postoperative patients. PLoS One 2015;10:e0131096. https://doi.org/10.1371/journal.pone.0131096
  49. Jeon MJ, Park JW, Han JM, et al. Serum antithyroglobulin antibodies interfere with thyroglobulin detection in fine-needle aspirates of metastatic neck nodes in papillary thyroid carcinoma. J Clin Endocrinol Metab 2013;98:153-160. https://doi.org/10.1210/jc.2012-2369
  50. Fiore E, Giustarini E, Mammoli C, et al. Favorable predictive value of thyroid autoimmunity in high aggressive breast cancer. J Endocrinol Invest 2007;30:734-738. https://doi.org/10.1007/BF03350810
  51. Jo K, Kim MH, Lim Y, et al. Lowered cutoff of lymph node fine-needle aspiration thyroglobulin in thyroid cancer patients with serum anti-thyroglobulin antibody. Eur J Endocrinol 2015;173:489-497. https://doi.org/10.1530/EJE-15-0344
  52. Baskin HJ. Detection of recurrent papillary thyroid carcinoma by thyroglobulin assessment in the needle washout after fine-needle aspiration of suspicious lymph nodes. Thyroid 2004;14:959-963. https://doi.org/10.1089/thy.2004.14.959
  53. Boi F, Baghino G, Atzeni F, Lai ML, Faa G, Mariotti S. The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti- Tg antibodies. J Clin Endocrinol Metab 2006;91:1364-1369. https://doi.org/10.1210/jc.2005-1705
  54. Duval M, Zanella AB, Cristo AP, Faccin CS, Graudenz MS, Maia AL. Impact of serum tsh and anti-thyroglobulin antibody levels on lymph node fine-needle aspiration thyroglobulin measurements in differentiated thyroid cancer patients. Eur Thyroid J 2017;6:292-297. https://doi.org/10.1159/000479682

Cited by

  1. Significance of Anti-TPO as an Early Predictive Marker in Thyroid Disease vol.2019, pp.None, 2018, https://doi.org/10.1155/2019/1684074
  2. SNMMI Procedure Standard for Scintigraphy for Differentiated Thyroid Cancer vol.48, pp.3, 2018, https://doi.org/10.2967/jnmt.120.243626
  3. Positive Thyroid Peroxidase Antibody and Thyroglobulin Antibody are Associated With Better Clinicopathologic Features of Papillary Thyroid Cancer vol.27, pp.4, 2018, https://doi.org/10.1016/j.eprac.2020.10.017
  4. A Mathematical Model of Thyroid Disease Response to Radiotherapy vol.9, pp.19, 2021, https://doi.org/10.3390/math9192365
  5. Prognostic Value of Serum Thyroglobulin and Anti-Thyroglobulin Antibody in Thyroid Carcinoma Patients following Thyroidectomy vol.11, pp.11, 2021, https://doi.org/10.3390/diagnostics11112080